<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stimulant use disorder: Treatment overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stimulant use disorder: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stimulant use disorder: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kyle Kampman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3437079593"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cocaine, methamphetamine, and other stimulant use disorders are significant public health problems [<a href="#rid1">1</a>]. Users of cocaine and methamphetamine have elevated rates of medical morbidity and utilization of health care resources [<a href="#rid2">2</a>].</p><p>Initial management decisions and pharmacologic options for the treatment of stimulant use disorder is discussed in this topic and is summarized in an algorithm  (<a class="graphic graphic_algorithm graphicRef140701" href="/z/d/graphic/140701.html" rel="external">algorithm 1</a>). Psychosocial interventions for stimulant use disorders are discussed separately. The epidemiology, clinical manifestations, course, consequences, assessment, and diagnosis of cocaine use disorder and methamphetamine use disorder are also described separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management"</a>.)</p><p></p><p class="headingAnchor" id="H1869878786"><span class="h1">PRINCIPLES OF TREATMENT</span><span class="headingEndMark"> — </span>Cocaine, methamphetamine, and diverted pharmaceutical stimulants have similar mechanisms of action and similar manifestations of addiction. This suggests that a treatment with evidence for efficacy in one disorder may be effective in the treatment of another [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication"</a>.)</p><p class="headingAnchor" id="H3303635201"><span class="h2">Continuing care principles</span><span class="headingEndMark"> — </span>We base the treatment of individuals with stimulant use disorder on the principles of the continuing care model as described below. Continuing care principles are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a> and  <a class="medical medical_review" href="/z/d/html/89215.html" rel="external">"Continuing care for addiction: Implementation"</a> and  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>We recognize that substance use disorders are often chronically recurring conditions that benefit from continuing care at varying levels of intensity rather than short-term treatment limited to periods of acute exacerbation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We base the intensity and number of psychosocial interventions used to treat a patient with stimulant use disorder on the patient’s clinical status, stimulant use disorder severity, and response to prior treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We address continued treatment resistance by increasing the intensity of treatment. This could involve additional modalities, more hours per week, and/or more structure or restriction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selection among treatment components is subject to patient preference, geographic variation in the availability of treatments/levels of care, and what payers will allow.</p><p></p><p class="headingAnchor" id="H2229033150"><span class="h2">Setting goals</span><span class="headingEndMark"> — </span>While we encourage complete sustained abstinence from stimulants in all individuals we treat for stimulant use disorder, we use shared decision making in establishing achievable treatment goals that lead to harm reduction and improvement in quality of life. Abstinence may be the most desirable outcome; however, it is often difficult to achieve. Furthermore, patients may find significant improvement in their lives with only a reduction of use.</p><p class="headingAnchor" id="H681241529"><span class="h1">PSYCHOSOCIAL INTERVENTION AS INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Only psychosocial interventions have demonstrated efficacy in reducing stimulant use in patients with stimulant use disorder [<a href="#rid4">4-6</a>]. Psychosocial interventions for stimulant use disorder include individual or group drug counseling including standard outpatient counseling and intensive outpatient therapy (IOT), cognitive-behavioral therapy (CBT), contingency management, and motivational interviewing. However, psychosocial treatments alone are insufficient for many patients, prompting research into the neurobiology of stimulant use disorder and trials of several augmenting medications.</p><p>Psychosocial interventions for stimulant use disorder are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management"</a>.)</p><p class="headingAnchor" id="H1720165965"><span class="h2">Choosing a psychosocial intervention</span><span class="headingEndMark"> — </span>Our initial treatment for stimulant use disorder is psychosocial intervention. Among psychosocial interventions, our choice is based on the severity of the disorder. Severity of the disorder is defined by the number of symptoms of the disorder that are present [<a href="#rid7">7</a>]. For example, using the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for stimulant use disorder, mild stimulant use disorder is characterized by the presence of two to three criteria, moderate stimulant use disorder is characterized by the presence of four to five criteria, and severe is characterized by the presence of six or more criteria  (<a class="graphic graphic_algorithm graphicRef140701" href="/z/d/graphic/140701.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H4016545772"><span class="h3">Mild stimulant use disorder</span><span class="headingEndMark"> — </span>For individuals with mild stimulant use disorder, we suggest first-line treatment with individual or group drug counseling. We monitor for response for three weeks. If the patient experiences only a partial response or no response to drug counseling, we suggest a transition to IOT combined with contingency management. If contingency management is unavailable, we encourage treatment with IOT and CBT. Motivational interviewing can be used at any time if needed. These therapies are described separately. (See  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management", section on 'Interventions'</a>.)</p><p class="headingAnchor" id="H3170439695"><span class="h3">Moderate or severe stimulant use disorder</span><span class="headingEndMark"> — </span>For patients with moderate or severe stimulant use disorder, we suggest first-line treatment with IOT combined with contingency management. When contingency management is unavailable, we encourage treatment with IOT and CBT. Motivational interviewing can be used at any time if needed (See  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management"</a>.)</p><p>In clinical trials, both contingency management and CBT have been found to be effective for stimulant use disorder [<a href="#rid4">4,6,8,9</a>]. While evidence for motivational interviewing, drug counseling and IOT is equivocal, in our clinical experience, they sometimes can help patients with stimulant use disorder to maintain abstinence [<a href="#rid5">5,10-13</a>]. Further discussion of choices of psychotherapy and their effectiveness can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management", section on 'Interventions'</a>.)</p><p class="headingAnchor" id="H227727328"><span class="h1">SUBSEQUENT TREATMENT</span></p><p class="headingAnchor" id="H2756775214"><span class="h2">Assessing response</span><span class="headingEndMark"> — </span>We assess treatment response in a variety of ways including whether goals were met, changes in quality of life, and patient satisfaction. Other useful measurements include the Addiction Severity Index and intermittent urine drug tests. (See <a class="local">'Setting goals'</a> above.)</p><p class="headingAnchor" id="H823864419"><span class="h2">Continuing care for treatment responders</span><span class="headingEndMark"> — </span>For individuals who respond to psychosocial treatment, we continue treatment using the continuing care model for up to one year. We encourage the individual to return to treatment for recurrence of symptoms or return to use. (See <a class="local">'Continuing care principles'</a> above.)</p><p class="headingAnchor" id="H822240661"><span class="h2">Combined treatment for suboptimal response</span><span class="headingEndMark"> — </span>For individuals who have suboptimal response after 8 to 12 weeks of the most intensive psychosocial treatments (eg, counseling, intensive outpatient therapy, contingency management or cognitive-behavioral therapy [CBT], motivational interviewing), we use pharmacologic augmentation. While limited and inconsistent evidence supports the use of pharmacologic treatment of stimulant use disorder [<a href="#rid14">14-26</a>], some studies suggest that the combination of medication (<a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, or <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>) and psychosocial interventions (contingency management or CBT) for stimulant use disorder may be more efficacious than either modality alone [<a href="#rid27">27-29</a>]. (See <a class="local">'Pharmacologic management'</a> below.)</p><p>As an example, in a randomized trial, 160 individuals with cocaine and opioid use disorder (maintained on <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>) were assigned to receive <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> or placebo in conjunction with either contingency management or a noncontingent voucher control over 12 weeks of treatment [<a href="#rid27">27</a>]. Cocaine-free and combined cocaine and opiate-free urine specimens increased more rapidly over time in patients assigned to receive desipramine or contingency management compared with controls. Patients assigned to receive both desipramine and contingency management had a higher percentage of drug free specimens over the course of the treatment as compared with those assigned to desipramine plus noncontingency management, placebo plus contingency management, or placebo plus noncontingency management (50 versus 29 versus 25 versus 29 percent, respectively).</p><p class="headingAnchor" id="H318782274"><span class="h1">PHARMACOLOGIC MANAGEMENT</span><span class="headingEndMark"> — </span>We use pharmacologic management combined with psychosocial treatments for suboptimal response to psychosocial treatment alone. Our choice of pharmacologic management is based on the stimulant being misused. However, when the individual is using more than one stimulant and the primary stimulant cannot be established, we use shared decision making to identify the substance most likely to be more problematic. There are no safety concerns in using any of the following treatments for either cocaine use disorder or methamphetamine use disorder  (<a class="graphic graphic_algorithm graphicRef140701" href="/z/d/graphic/140701.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1899172925"><span class="h2">Cocaine use disorder</span><span class="headingEndMark"> — </span>We typically try medications for cocaine use disorder sequentially in the order listed below. Evidence supporting the usefulness of any of the medications listed is mixed. Our recommendations are based on limited data.</p><p class="headingAnchor" id="H1801650931"><span class="h3">Topiramate as first choice</span><span class="headingEndMark"> — </span>We use <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, a GABAergic medication as augmentation in individuals refractory to psychosocial treatments who do not have a contraindication to its use (eg, kidney stones, glaucoma).</p><p>GABA is the primary inhibitory neurotransmitter in the central nervous system. Activation of GABAergic neurons leads to decreased activation in the dopaminergic reward system [<a href="#rid30">30-35</a>]. These effects may help to prevent relapse either by blocking cocaine-induced euphoria, or by reducing craving caused by exposure to conditioned reminders of prior cocaine use.</p><p><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> may be used to augment standard psychosocial treatment or may be used when psychosocial treatments fail or when efficacious treatments are not available. We begin topiramate at 25 mg daily. We increase by 25 to 50 mg weekly to a target dose of 150 to 300 mg per day in divided dose. If tolerated, we typically monitor over three months for efficacy. If ineffective, we taper topiramate slowly (eg, 50 mg/week) when discontinuing. If effective topiramate can be continued as long as a patient needs it. There is no established duration of treatment for any pharmacotherapy for substance use disorders.</p><p><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> appears to be effective in the treatment of cocaine use disorder [<a href="#rid24">24,25,36</a>]. However, further studies are warranted. As examples, treatment with topiramate led to greater likelihood of abstinence and improved outcome versus placebo in the following trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 13-week trial, 40 patients with cocaine use disorder were randomly assigned to treatment with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> (200 mg daily) or placebo [<a href="#rid36">36</a>]. Subjects assigned to receive topiramate were more likely to be abstinent during the last five weeks of the trial. In a secondary analysis among patients who returned for at least one visit after receiving medications, patients in the topiramate group were more likely to achieve at least three weeks of continuous abstinence from cocaine compared with patients in the placebo group (59 versus 26 percent). Topiramate patients were more likely than placebo patients to be rated “very much improved” at their last visit (71 versus 32 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 12-week trial, 142 patients with cocaine use disorder who were treated with CBT were randomly assigned to treatment with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> or placebo. Individuals in the topiramate treatment group had a greater weekly proportion of cocaine nonuse days compared with those in the placebo group (13.3 versus 5.3 percent) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Additionally, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> may be effective in individuals with comorbid alcohol use disorder:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 13-week trial, 170 patients with cocaine use disorder and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) alcohol dependence who were in weekly individual psychotherapy were randomly assigned augmentation with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> (300 mg daily) or placebo [<a href="#rid24">24</a>]. While differences prevention of relapse were not noted, subjects receiving topiramate were more likely to achieve three weeks of continuous abstinence from cocaine during the trial compared with the placebo group (20 versus 6 percent).</p><p></p><p class="headingAnchor" id="H1717002511"><span class="h3">Long-acting amphetamines</span><span class="headingEndMark"> — </span>We prefer to use long-acting amphetamines as the next agent for individuals who do not respond to treatment with <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>. These agents block the same monoamine transporters as cocaine, but their relatively slower uptake and longer duration of action make them less likely to be misused [<a href="#rid37">37</a>]. This is analogous to the use of <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> in the treatment of opioid use disorder.</p><p>The use of long-acting stimulants for the treatment of cocaine use disorder should be done after a discussion of the risks (eg, misuse) and benefits with the patient. When prescribing long-acting stimulants to individuals with stimulant use disorder, we provide limited amount of medication and monitor for misuse or diversion at frequent intervals throughout the treatment.</p><p>We typically titrate long-acting amphetamines at the same titration rate and dose used in the treatment of attention deficit hyperactivity disorder in adults. For example, if using long-acting <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a>/<a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> mixed salts, we would begin at 20 mg daily and increase by 10 mg at weekly intervals to a maximum dose of 60 mg per day. If ineffective (eg, after three months), we taper the medication over several weeks. (See  <a class="medical medical_review" href="/z/d/html/118534.html" rel="external">"Attention deficit hyperactivity disorder in adults: Treatment overview", section on 'Stimulants as preferred pharmacologic treatment'</a>.)</p><p>Limited data support the use of stimulants in the treatment of cocaine use disorder. Additionally, in some trials, treatment retention has been poor [<a href="#rid15">15-17</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 12-week trial, 73 patients with treatment-refractory heroin and cocaine dependence were randomly assigned to treatment with oral dexamphetamine-SR 60 mg/day or placebo [<a href="#rid14">14</a>]. Both groups received <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> and diacetylmorphine (heroin-assisted treatment). Subjects treated with dexamphetamine-SR had fewer days of cocaine use as compared with individuals treated with placebo (mean 44.9 versus 60.6 days). Secondary outcomes (eg, consecutive days reported abstinence, days abstinent in final four weeks of study) favored the dexamphetamine group over the placebo group. Eighty-nine percent of participants completed the trial. No serious adverse events occurred in dexamphetamine-treated patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an eight-week trial, 82 patients with cocaine use disorder were randomly assigned to treatment with sustained methamphetamine, immediate-release methamphetamine, or placebo [<a href="#rid17">17</a>]. Patients in the sustained-release methamphetamine group submitted fewer cocaine-positive urine drug screens during the trial compared with the immediate-release and placebo groups (29 versus 66 and 60 percent). Only 32 percent of patients completed the trial.</p><p></p><p class="headingAnchor" id="H2731714731"><span class="h3">Combination of topiramate and long-acting amphetamine</span><span class="headingEndMark"> — </span>For individuals with inadequate response to the above treatments, we use a combination of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> and long-acting <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> as the next choice. The combination of topiramate and long-acting amphetamine in the form of long-acting mixed amphetamine salts (MAS-ER) has shown efficacy for the treatment of cocaine use disorder [<a href="#rid38">38-40</a>].</p><p>For example, in a randomized trial, 81 individuals with cocaine use disorder were assigned to 12 weeks of treatment with either a combination of MAS-ER plus <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> or double placebo [<a href="#rid39">39</a>]. MAS-ER was titrated to maximum dose of 60 mg/day over 2 weeks, topiramate was titrated to maximum dose of 300 mg/day over 6 weeks. More patients in the topiramate plus MAS-ER group achieved three consecutive weeks of abstinence during the trial as compared with the placebo group (33.3 versus 16.7 percent, respectively). The combination treatment was most effective for participants with a high baseline frequency of cocaine use. This was replicated in another trial in which 127 adults with cocaine use disorder were randomly assigned to 12 weeks treatment with the combination of topiramate (maximum dose 200 mg/day) and MAS-ER (maximum 60mg/day) or placebo [<a href="#rid40">40</a>]. The proportion of participants achieving three abstinent weeks at the end of the trial was greater in patients treated with topiramate and MAS-ER compared with the placebo group (14 versus 0 percent, respectively). Further trials are warranted.</p><p class="headingAnchor" id="H779771671"><span class="h3">Other agents with limited supporting data</span><span class="headingEndMark"> — </span>We use the following agents only after the above agents have been ineffective.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modafinil</strong><strong> </strong>– <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">Modafinil</a>, a stimulant used to treat narcolepsy and shift-work sleep disorder, has been studied as an agent to increase abstinence and reduce cocaine withdrawal symptoms in individuals with cocaine use disorder [<a href="#rid18">18,20,21,41-46</a>].</p><p></p><p class="bulletIndent1">Clinical trials of <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> in the treatment of cocaine use disorder have shown mixed results with some results finding evidence of benefit [<a href="#rid18">18,21,45</a>] and others not showing benefit [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disulfiram</strong> – <a class="drug drug_general" data-topicid="9379" href="/z/d/drug information/9379.html" rel="external">Disulfiram</a> is thought to effect cocaine use by decreasing the reinforcing properties of cocaine or by making cocaine use aversive [<a href="#rid47">47-49</a>]. It is also only indicated for patients committed to total abstinence from alcohol since it will provoke a disulfiram-alcohol reaction in the presence of alcohol. Limited data support its use in the treatment of cocaine use disorder and further studies are warranted. [<a href="#rid22">22,23,50-52</a>]. (See  <a class="medical medical_review" href="/z/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management", section on 'Disulfiram'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidepressants </strong>– Little to no evidence supports the use of antidepressants in the treatment of cocaine use disorder [<a href="#rid27">27,53-58</a>]. In a small randomized trial, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> appeared to improve treatment retention in the outpatient treatment of primary crack cocaine dependence although similar finding in terms of cocaine use and craving were reported in this [<a href="#rid53">53</a>] and other studies [<a href="#rid54">54</a>]. In a single trial, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> 40 mg but not citalopram 20 mg appeared to improve duration of abstinence and likelihood of cocaine negative urine drug screen [<a href="#rid59">59</a>]. Small trials examining treatment with <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> have shown mixed results for sustained abstinence as compared with placebo; however, interpretation is limited due to heterogeneity of methods and small sample sizes [<a href="#rid55">55-57</a>].</p><p></p><p class="bulletIndent1">We reserve the use of <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> for individuals with cocaine use disorder only after the above treatments have been ineffective.</p><p></p><p class="headingAnchor" id="H3554878513"><span class="h2">Methamphetamine use disorder</span><span class="headingEndMark"> — </span>As with cocaine use disorder, we use medication management only after psychosocial treatment has been ineffective. Trials investigating <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>, and a combination of bupropion and <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> have shown conflicting results with some showing some benefit; however, further trials with greater number of subjects are warranted [<a href="#rid60">60-68</a>]. (See <a class="local">'Psychosocial intervention as initial treatment'</a> above.)</p><p class="headingAnchor" id="H2722621458"><span class="h3">Bupropion with naltrexone</span><span class="headingEndMark"> — </span>Among medication treatments our first choice is combination of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>. </p><p>In clinical trials, treatment with combination injectable extended-release <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> 380 mg monthly with 450 mg <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> daily appears to be effective in the treatment of methamphetamine use disorder [<a href="#rid60">60,69</a>]. In a clinical trial, 403 subjects with methamphetamine use disorder were randomly assigned to receive either a combination of injectable extended-release naltrexone with oral extended-release bupropion or placebo [<a href="#rid60">60</a>]. In this study, the naltrexone was given by injection at 380 mg every 3 weeks rather than at the approved frequency of every 4 weeks. Bupropion was begun at 150 mg extended release and increased to 450 mg over the course of three days. At 12 weeks, overall weighted response rates (three out of four methamphetamine negative urine samples) were low in both groups but higher in the treatment group than in the placebo group (14 versus 3 percent). Secondary outcomes such as percentage of participants with negative urine samples and methamphetamine craving scores favored the treatment group.</p><p class="headingAnchor" id="H1552654130"><span class="h3">Mirtazapine</span><span class="headingEndMark"> — </span>If <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> are ineffective our next choice is typically monotherapy with <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>. Our target dose with mirtazapine is 30 mg nightly.</p><p>Two clinical trials and a subsequent meta-analysis suggest that <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> may be efficacious in the treatment of methamphetamine use disorder [<a href="#rid61">61-63</a>]. In one trial including 120 individuals with methamphetamine use disorder, individuals receiving mirtazapine had fewer positive urine tests at 24 weeks (63 percent versus 74 percent; relative risk 0.75, 95% CI 0.56-1.00) and 36 weeks (71 versus 88 percent; relative risk 0.73, 95% CI 0.57-0.96) than those in placebo group [<a href="#rid62">62</a>]. Both mirtazapine trials were conducted in a special population of adult patients (cisgender men, transgender men, and transgender women who had sex with men) with stimulant use disorder who were sexually active.</p><p class="headingAnchor" id="H835812631"><span class="h3">Methylphenidate</span><span class="headingEndMark"> — </span>Systematic reviews and meta-analyses show limited support for the use of <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> in the treatment of methamphetamine use disorder. For example, in a meta-analysis of five trials including 642 participants no effect of treatment with psychostimulants for end-of-study abstinence (odds ratio 0.97, 95% CI 0.65-1.45) [<a href="#rid66">66</a>]. Additionally, the pooled estimate from 14 studies including 1184 participants showed no effect of psychostimulants for treatment retention (odds ratio 1.2, 95% CI 0.91-1.58).</p><p>In another meta-analysis, there was low-strength evidence from two randomized trials that <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> reduced methamphetamine/<a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> (MA/A) use: 6.5 versus 2.8 percent MA/A negative urine drug screens in one study (n = 34, p = 0.008) and 23 versus 16 percent in another study (n = 54, p = 0.047) [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H911816892"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115010.html" rel="external">"Society guideline links: Stimulant use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/134144.html" rel="external">"Society guideline links: Cocaine use and cocaine use disorder"</a>.)</p><p class="headingAnchor" id="H1114169001"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuing care principles</strong> – We use continuing care principles in the treatment of individuals with stimulant use disorder. Continuing care principles suggest that for individuals with substance use disorder who do not achieve abstinence or relapse following initial interventions, the intensity of the patient’s treatment should be increased. This could involve additional modalities, more hours per week, and/or more structure or restriction. (See <a class="local">'Continuing care principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial intervention </strong>–<strong> </strong>Our initial treatment for stimulant use disorder is a psychosocial intervention. Among psychosocial interventions, our choice is based on the severity of the disorder. An algorithm describes the management of stimulant use disorder  (<a class="graphic graphic_algorithm graphicRef140701" href="/z/d/graphic/140701.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild stimulant use disorder</strong> – For patients with mild stimulant use disorder, we suggest first line treatment with individual or group drug counseling, rather than other treatments (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Choosing a psychosocial intervention'</a> above.)</p><p></p><p class="bulletIndent2">For patients with mild stimulant use disorder who do not achieve abstinence after three weeks of individual or group drug counseling we suggest transition to intensive outpatient therapy (IOT) combined with contingency management (if available) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Motivational interviewing can be used at any time if needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate or severe stimulant use disorder</strong> – For patients with moderate or severe stimulant use disorder, we suggest first-line treatment with IOT combined with contingency management (if available) along with motivational interviewing (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Choosing a psychosocial intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment </strong>–<strong> </strong>For individuals with stimulant use disorder who respond to psychosocial treatment we continue treatment using the continuing care model for up to one year. We encourage the individual to return to treatment for recurrence of symptoms or return to use. (See <a class="local">'Subsequent treatment'</a> above.)</p><p></p><p class="bulletIndent1">For individuals who have suboptimal response after 8 to 12 weeks of the most intensive psychosocial treatments (eg, counseling, IOT, contingency management or cognitive-behavioral therapy, motivational interviewing), we use pharmacologic augmentation. (See <a class="local">'Combined treatment for suboptimal response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic management </strong>–<strong> </strong>We use pharmacologic management combined with psychosocial treatments for suboptimal response to psychosocial treatment alone. Our choice of pharmacologic management is based on the stimulant being misused  (<a class="graphic graphic_algorithm graphicRef140701" href="/z/d/graphic/140701.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cocaine use disorder</strong> – We suggest <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> as the first choice for pharmacologic augmentation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If this is ineffective our next choice is long-acting amphetamines, then combining topiramate with a long-acting <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a>. (See <a class="local">'Cocaine use disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methamphetamine use disorder </strong>–<strong> </strong>We suggest the combination of <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> as the first choice in the pharmacologic augmentation of methamphetamine use disorder (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> and <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> are other treatment options. (See <a class="local">'Methamphetamine use disorder'</a> above.)</p><p></p><p class="headingAnchor" id="H3971229836"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David A Gorelick, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Substance Abuse and Mental Health Services Administration. Results from the 2020 National Survey of Drug Use and Health (NSDUH). Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2021.</li><li class="breakAll">Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network, 2008: National Estimates of Drug-Related Emergency Department Visits. HHS Publication no. SMA 11-4618, Department of Health and Human Services, Rockville, MD 2011.</li><li class="breakAll">Haney M. Neurobiology of stimulants. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Galanter M, Kleber HD (Eds), American Psychiatric Publishing, Inc, 2008. p.143.</li><li><a class="nounderline abstract_t">Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004; 99:708.</a></li><li><a class="nounderline abstract_t">Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493.</a></li><li><a class="nounderline abstract_t">Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol 1998; 66:832.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Bentzley BS, Han SS, Neuner S, et al. Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4:e218049.</a></li><li><a class="nounderline abstract_t">Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006; 101:267.</a></li><li><a class="nounderline abstract_t">McLellan AT, Hagan TA, Meyers K, et al. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis 1997; 16:57.</a></li><li><a class="nounderline abstract_t">Coviello DM, Alterman AI, Rutherford MJ, et al. The effectiveness of two intensities of psychosocial treatment for cocaine dependence. Drug Alcohol Depend 2001; 61:145.</a></li><li><a class="nounderline abstract_t">Stein MD, Herman DS, Anderson BJ. A motivational intervention trial to reduce cocaine use. J Subst Abuse Treat 2009; 36:118.</a></li><li><a class="nounderline abstract_t">Rohsenow DJ, Monti PM, Martin RA, et al. Motivational enhancement and coping skills training for cocaine abusers: effects on substance use outcomes. Addiction 2004; 99:862.</a></li><li><a class="nounderline abstract_t">Nuijten M, Blanken P, van de Wetering B, et al. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet 2016; 387:2226.</a></li><li><a class="nounderline abstract_t">Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001; 21:522.</a></li><li><a class="nounderline abstract_t">Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004; 29:969.</a></li><li><a class="nounderline abstract_t">Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009; 101:34.</a></li><li><a class="nounderline abstract_t">Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30:205.</a></li><li><a class="nounderline abstract_t">Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104:133.</a></li><li><a class="nounderline abstract_t">Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012; 43:303.</a></li><li><a class="nounderline abstract_t">Kampman KM, Lynch KG, Pettinati HM, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 2015; 155:105.</a></li><li><a class="nounderline abstract_t">Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264.</a></li><li><a class="nounderline abstract_t">George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000; 47:1080.</a></li><li><a class="nounderline abstract_t">Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013; 133:94.</a></li><li><a class="nounderline abstract_t">Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013; 70:1338.</a></li><li><a class="nounderline abstract_t">Somoza EC, Winship D, Gorodetzky CW, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013; 70:630.</a></li><li><a class="nounderline abstract_t">Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70:315.</a></li><li><a class="nounderline abstract_t">Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63:219.</a></li><li><a class="nounderline abstract_t">Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33:367.</a></li><li><a class="nounderline abstract_t">Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998; 51:627.</a></li><li><a class="nounderline abstract_t">Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52:473.</a></li><li><a class="nounderline abstract_t">Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41 Suppl 1:S10.</a></li><li><a class="nounderline abstract_t">Gerasimov MR, Ashby CR Jr, Gardner EL, et al. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999; 34:11.</a></li><li><a class="nounderline abstract_t">Dewey SL, Smith GS, Logan J, et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992; 12:3773.</a></li><li><a class="nounderline abstract_t">Dewey SL, Chaurasia CS, Chen CE, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997; 25:393.</a></li><li><a class="nounderline abstract_t">Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41. HHS Publication no. (SMA) 11-4658, Substance abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2011.</li><li><a class="nounderline abstract_t">Rush CR, Stoops WW, Lile JA, et al. Topiramate-phentermine combinations reduce cocaine self-administration in humans. Drug Alcohol Depend 2021; 218:108413.</a></li><li><a class="nounderline abstract_t">Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012; 72:950.</a></li><li><a class="nounderline abstract_t">Levin FR, Mariani JJ, Pavlicova M, et al. Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. Drug Alcohol Depend 2020; 206:107700.</a></li><li><a class="nounderline abstract_t">Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci 2003; 1003:328.</a></li><li><a class="nounderline abstract_t">Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301:1148.</a></li><li><a class="nounderline abstract_t">Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70:29.</a></li><li><a class="nounderline abstract_t">Malcolm R, Donovan C, Devane A, et al. Influence of modafinil, 400 or 800 mg/day on subjective effects of intravenous cocaine in nontreatment seeking volunteers. Drug Alcohol Depend 2002; 66:S110.</a></li><li><a class="nounderline abstract_t">Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008; 33:761.</a></li><li><a class="nounderline abstract_t">Touret M, Sallanon-Moulin M, Fages C, et al. Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain. Brain Res Mol Brain Res 1994; 26:123.</a></li><li><a class="nounderline abstract_t">McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52:27.</a></li><li><a class="nounderline abstract_t">Hameedi FA, Rosen MI, McCance-Katz EF, et al. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 1995; 37:560.</a></li><li><a class="nounderline abstract_t">Karamanakos PN, Pappas P, Stephanou P, Marselos M. Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism. Pharmacol Toxicol 2001; 88:106.</a></li><li><a class="nounderline abstract_t">Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93:713.</a></li><li><a class="nounderline abstract_t">Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000; 95:219.</a></li><li><a class="nounderline abstract_t">Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008; 33:651.</a></li><li><a class="nounderline abstract_t">Batki SL, Washburn AM, Delucchi K, Jones RT. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996; 41:137.</a></li><li><a class="nounderline abstract_t">Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995; 15:163.</a></li><li><a class="nounderline abstract_t">Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46:117.</a></li><li><a class="nounderline abstract_t">Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49:894.</a></li><li><a class="nounderline abstract_t">Campbell J, Nickel EJ, Penick EC, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict 2003; 12:122.</a></li><li><a class="nounderline abstract_t">Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40:125.</a></li><li><a class="nounderline abstract_t">Suchting R, Green CE, de Dios C, et al. Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug Alcohol Depend 2021; 228:109054.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med 2021; 384:140.</a></li><li><a class="nounderline abstract_t">Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry 2011; 68:1168.</a></li><li><a class="nounderline abstract_t">Coffin PO, Santos GM, Hern J, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry 2020; 77:246.</a></li><li><a class="nounderline abstract_t">Naji L, Dennis B, Rosic T, et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis. Drug Alcohol Depend 2022; 232:109295.</a></li><li><a class="nounderline abstract_t">Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008; 33:1162.</a></li><li><a class="nounderline abstract_t">Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96:222.</a></li><li><a class="nounderline abstract_t">Bhatt M, Zielinski L, Baker-Beal L, et al. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Syst Rev 2016; 5:189.</a></li><li><a class="nounderline abstract_t">Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction 2019; 114:2122.</a></li><li><a class="nounderline abstract_t">Bakouni H, Sharafi H, Bahremand A, et al. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend 2023; 253:111018.</a></li><li><a class="nounderline abstract_t">Levander XA, Carmody T, Cook RR, et al. A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction 2023; 118:1320.</a></li></ol></div><div id="topicVersionRevision">Topic 106878 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Substance Abuse and Mental Health Services Administration. Results from the 2020 National Survey of Drug Use and Health (NSDUH). Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network, 2008: National Estimates of Drug-Related Emergency Department Visits. HHS Publication no. SMA 11-4618, Department of Health and Human Services, Rockville, MD 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haney M. Neurobiology of stimulants. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Galanter M, Kleber HD (Eds), American Psychiatric Publishing, Inc, 2008. p.143.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139869" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359461" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9803702" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9803702" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961037" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445555" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083825" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11137279" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effectiveness of two intensities of psychosocial treatment for cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657938" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A motivational intervention trial to reduce cocaine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200582" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Motivational enhancement and coping skills training for cocaine abusers: effects on substance use outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27015909" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11593078" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15039761" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19058926" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525998" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A double-blind, placebo-controlled trial of modafinil for cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560290" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Modafinil for the treatment of cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377391" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A double-blind, placebo-controlled trial of modafinil for cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320827" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993114" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10862808" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810644" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132249" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Topiramate for the treatment of cocaine addiction: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23575810" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12757969" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461866" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613964" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9710056" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Topiramate increases cerebral GABA in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025774" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768293" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459167" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357114" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9097399" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : GABAergic attenuation of cocaine-induced dopamine release and locomotor activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283944" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A pilot trial of topiramate for the treatment of cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283944" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A pilot trial of topiramate for the treatment of cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33290875" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topiramate-phentermine combinations reduce cocaine self-administration in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795453" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31753736" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684456" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Glutamatergic agents for cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293415" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681523" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Influence of modafinil, 400 or 800 mg/day on subjective effects of intravenous cocaine in nontreatment seeking volunteers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568397" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Smoked cocaine self-administration is decreased by modafinil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854038" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788003" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Disulfiram effects on acute cocaine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619981" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11169169" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692270" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10723850" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079068" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8809502" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A controlled trial of fluoxetine in crack cocaine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635993" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492422" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Desipramine facilitation of initial cocaine abstinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1444728" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746087" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8745134" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34600245" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497547" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bupropion and Naltrexone in Methamphetamine Use Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22065532" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mirtazapine to reduce methamphetamine use: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825466" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35066460" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581531" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bupropion for the treatment of methamphetamine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18468815" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27842569" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31328345" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37979478" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36864016" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
